Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in s...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2014-09, Vol.93 (3), p.224-228 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 3 |
| container_start_page | 224 |
| container_title | European journal of haematology |
| container_volume | 93 |
| creator | Bjørn, Mads Emil Andersen, Christen Lykkegaard Jensen, Morten Krogh Hasselbalch, Hans C. |
| description | Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL‐40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL‐40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL‐40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL‐40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs. |
| doi_str_mv | 10.1111/ejh.12332 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1553707307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1553707307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4682-c26ea1049e6755e2cd3c3a7f25df10d3e869a1d2e96bded8f9d7cc154b10c9373</originalsourceid><addsrcrecordid>eNp1kMFu1DAQQC0EokvhwA8gH-GQdmwn8fqIVqWFLq2ECggulmNPqIsTb2NvIX9fl217w5e5vHnyPEJeMzhg5R3i1eUB40LwJ2TBWoAKWlBPyQIU8Kqua7ZHXqR0BQBcMfmc7PG6XaqlbBZkXPnJboPJfvxFf5yuqxqoH-kwY4i976aYfKKGbmLGMXsT6BhvMNDOx8FMv3GisafOJzQJqbHZ3_g8UzM6mi-xiPpghsHkOM00ZZPxJXnWm5Dw1f3cJ18_HF2sTqr1-fHH1ft1ZcvPeGV5i4ZBrbCVTYPcOmGFkT1vXM_ACVy2yjDHUbWdQ7fslZPWsqbuGFglpNgnb3fezRSvt5iyHnyyGIIZMW6TZk0jJEgBd-i7HWrLsWnCXm8mX46bNQN9l1eXvPpf3sK-udduuwHdI_nQswCHO-CPDzj_36SPPp08KKvdhk8Z_z5ulLi6lUI2-vvZsf787ULIL_KnBnELex2UaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1553707307</pqid></control><display><type>article</type><title>Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Bjørn, Mads Emil ; Andersen, Christen Lykkegaard ; Jensen, Morten Krogh ; Hasselbalch, Hans C.</creator><creatorcontrib>Bjørn, Mads Emil ; Andersen, Christen Lykkegaard ; Jensen, Morten Krogh ; Hasselbalch, Hans C.</creatorcontrib><description>Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL‐40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL‐40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL‐40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL‐40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.12332</identifier><identifier>PMID: 24689875</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adipokines - blood ; Adipokines - genetics ; Aged ; biomarker ; Biomarkers - blood ; Case-Control Studies ; Chitinase-3-Like Protein 1 ; chronic inflammation ; cytokines ; Female ; Gene Expression ; Humans ; Inflammation - blood ; Inflammation - genetics ; Inflammation - pathology ; JAK2V617F ; Lectins - blood ; Lectins - genetics ; Male ; Middle Aged ; myeloproliferative neoplasia (MPN) ; Polycythemia Vera - blood ; Polycythemia Vera - genetics ; Polycythemia Vera - pathology ; Primary Myelofibrosis - blood ; Primary Myelofibrosis - genetics ; Primary Myelofibrosis - pathology ; Severity of Illness Index ; Thrombocythemia, Essential - blood ; Thrombocythemia, Essential - genetics ; Thrombocythemia, Essential - pathology ; YKL-40</subject><ispartof>European journal of haematology, 2014-09, Vol.93 (3), p.224-228</ispartof><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4682-c26ea1049e6755e2cd3c3a7f25df10d3e869a1d2e96bded8f9d7cc154b10c9373</citedby><cites>FETCH-LOGICAL-c4682-c26ea1049e6755e2cd3c3a7f25df10d3e869a1d2e96bded8f9d7cc154b10c9373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.12332$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.12332$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24689875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bjørn, Mads Emil</creatorcontrib><creatorcontrib>Andersen, Christen Lykkegaard</creatorcontrib><creatorcontrib>Jensen, Morten Krogh</creatorcontrib><creatorcontrib>Hasselbalch, Hans C.</creatorcontrib><title>Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL‐40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL‐40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL‐40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL‐40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.</description><subject>Adipokines - blood</subject><subject>Adipokines - genetics</subject><subject>Aged</subject><subject>biomarker</subject><subject>Biomarkers - blood</subject><subject>Case-Control Studies</subject><subject>Chitinase-3-Like Protein 1</subject><subject>chronic inflammation</subject><subject>cytokines</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Inflammation - blood</subject><subject>Inflammation - genetics</subject><subject>Inflammation - pathology</subject><subject>JAK2V617F</subject><subject>Lectins - blood</subject><subject>Lectins - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>myeloproliferative neoplasia (MPN)</subject><subject>Polycythemia Vera - blood</subject><subject>Polycythemia Vera - genetics</subject><subject>Polycythemia Vera - pathology</subject><subject>Primary Myelofibrosis - blood</subject><subject>Primary Myelofibrosis - genetics</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Severity of Illness Index</subject><subject>Thrombocythemia, Essential - blood</subject><subject>Thrombocythemia, Essential - genetics</subject><subject>Thrombocythemia, Essential - pathology</subject><subject>YKL-40</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFu1DAQQC0EokvhwA8gH-GQdmwn8fqIVqWFLq2ECggulmNPqIsTb2NvIX9fl217w5e5vHnyPEJeMzhg5R3i1eUB40LwJ2TBWoAKWlBPyQIU8Kqua7ZHXqR0BQBcMfmc7PG6XaqlbBZkXPnJboPJfvxFf5yuqxqoH-kwY4i976aYfKKGbmLGMXsT6BhvMNDOx8FMv3GisafOJzQJqbHZ3_g8UzM6mi-xiPpghsHkOM00ZZPxJXnWm5Dw1f3cJ18_HF2sTqr1-fHH1ft1ZcvPeGV5i4ZBrbCVTYPcOmGFkT1vXM_ACVy2yjDHUbWdQ7fslZPWsqbuGFglpNgnb3fezRSvt5iyHnyyGIIZMW6TZk0jJEgBd-i7HWrLsWnCXm8mX46bNQN9l1eXvPpf3sK-udduuwHdI_nQswCHO-CPDzj_36SPPp08KKvdhk8Z_z5ulLi6lUI2-vvZsf787ULIL_KnBnELex2UaQ</recordid><startdate>201409</startdate><enddate>201409</enddate><creator>Bjørn, Mads Emil</creator><creator>Andersen, Christen Lykkegaard</creator><creator>Jensen, Morten Krogh</creator><creator>Hasselbalch, Hans C.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201409</creationdate><title>Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state</title><author>Bjørn, Mads Emil ; Andersen, Christen Lykkegaard ; Jensen, Morten Krogh ; Hasselbalch, Hans C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4682-c26ea1049e6755e2cd3c3a7f25df10d3e869a1d2e96bded8f9d7cc154b10c9373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adipokines - blood</topic><topic>Adipokines - genetics</topic><topic>Aged</topic><topic>biomarker</topic><topic>Biomarkers - blood</topic><topic>Case-Control Studies</topic><topic>Chitinase-3-Like Protein 1</topic><topic>chronic inflammation</topic><topic>cytokines</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Inflammation - blood</topic><topic>Inflammation - genetics</topic><topic>Inflammation - pathology</topic><topic>JAK2V617F</topic><topic>Lectins - blood</topic><topic>Lectins - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>myeloproliferative neoplasia (MPN)</topic><topic>Polycythemia Vera - blood</topic><topic>Polycythemia Vera - genetics</topic><topic>Polycythemia Vera - pathology</topic><topic>Primary Myelofibrosis - blood</topic><topic>Primary Myelofibrosis - genetics</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Severity of Illness Index</topic><topic>Thrombocythemia, Essential - blood</topic><topic>Thrombocythemia, Essential - genetics</topic><topic>Thrombocythemia, Essential - pathology</topic><topic>YKL-40</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bjørn, Mads Emil</creatorcontrib><creatorcontrib>Andersen, Christen Lykkegaard</creatorcontrib><creatorcontrib>Jensen, Morten Krogh</creatorcontrib><creatorcontrib>Hasselbalch, Hans C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bjørn, Mads Emil</au><au>Andersen, Christen Lykkegaard</au><au>Jensen, Morten Krogh</au><au>Hasselbalch, Hans C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2014-09</date><risdate>2014</risdate><volume>93</volume><issue>3</issue><spage>224</spage><epage>228</epage><pages>224-228</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL‐40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL‐40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL‐40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL‐40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24689875</pmid><doi>10.1111/ejh.12332</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2014-09, Vol.93 (3), p.224-228 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1553707307 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | Adipokines - blood Adipokines - genetics Aged biomarker Biomarkers - blood Case-Control Studies Chitinase-3-Like Protein 1 chronic inflammation cytokines Female Gene Expression Humans Inflammation - blood Inflammation - genetics Inflammation - pathology JAK2V617F Lectins - blood Lectins - genetics Male Middle Aged myeloproliferative neoplasia (MPN) Polycythemia Vera - blood Polycythemia Vera - genetics Polycythemia Vera - pathology Primary Myelofibrosis - blood Primary Myelofibrosis - genetics Primary Myelofibrosis - pathology Severity of Illness Index Thrombocythemia, Essential - blood Thrombocythemia, Essential - genetics Thrombocythemia, Essential - pathology YKL-40 |
| title | Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T14%3A57%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20YKL-40%20in%20myelofibrosis%20a%20potential%20novel%20biomarker%20of%20disease%20activity%20and%20the%20inflammatory%20state&rft.jtitle=European%20journal%20of%20haematology&rft.au=Bj%C3%B8rn,%20Mads%20Emil&rft.date=2014-09&rft.volume=93&rft.issue=3&rft.spage=224&rft.epage=228&rft.pages=224-228&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.12332&rft_dat=%3Cproquest_cross%3E1553707307%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1553707307&rft_id=info:pmid/24689875&rfr_iscdi=true |